Stocks to Watch: MiMedx Group, Nokia
By Ben Glickman
MiMedx Group said on Friday it received an FDA warning letter related to the classification of its product Axiofill. The regulator has reaffirmed that the company's treatment doesn't qualify as a Section 361 product, meaning it likely requires pre-market review. Shares fall 6.5% to $8.20 after-hours.
Nokia expects to miss its 2023 financial outlook as license-renewal discussions stretch into 2024. The company expects to miss guidance on net sales, comparable operating margin and free cash flow, and can't provide preliminary financial results for the quarter because the reporting period hasn't concluded. Shares fall 1.5% to $3.37 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 29, 2023 18:24 ET (23:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Capital Allocation
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?